Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORIA
2016-000671-25Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) and chronic heart failure (CHF) comparing Vericiguat + standard of care with Placebo + standard of care (2 arms). Started Jun 2016; status: completed.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2016-000671-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000671-25.